Abstract
This article reviews investigations over the last 15 years into the development of multi-nuclear platinum complexes as anti-cancer agents, with the purpose of providing an insight into the benefits of, and reasons for, their success. The cytotoxicity of multi-nuclear platinum complexes is compared, as is their ability to overcome both natural and acquired drug resistance. Possible structure-activity relationships are outlined. While the multi-nuclear platinum complexes exhibit excellent anti-cancer activity, the associated toxicity could limit their clinical use. Given that these complexes derive their activity from the novel adducts they form with DNA, three important aspects of their binding are discussed; their DNA pre-association, the DNA adducts formed and the DNA conformational changes induced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
